Navigation Links
CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
Date:10/6/2010

MISSISSAUGA, Ontario, Oct. 6 /PRNewswire/ -- Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH), has authored a cover story for this month's Medical Device & Diagnostic Industry Magazine (MD+DI) which addresses improvements in diagnostic times using point-of-care technology. In the article, titled "Improving Diagnosis Times with New Point-of-Care Technology," Dr. Gawad reviews the in-vitro diagnostics market and the growth of point-of-care testing.

In addition to reviewing other point-of-care devices, Dr. Gawad describes the operation of the QL Care Analyzer™, CardioGenics' point-of-care immunoassay platform that will allow a heart attack diagnosis to be made in as little as 15 minutes vs. the national average of 2.8 hours required for test results from a central lab. CardioGenics expects to submit to the FDA a 510K application for the QL Care Analyzer™ (and its first cardiac test, Troponin-I) during Q1 2011 and to have both commercialized by Q2 2011.

The article can be accessed online at:

http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology

About Medical Device & Diagnostics Industry

Medical Device & Diagnostic Industry is a leading monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnostic products. The goal of MD&DI is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. MD&DI is published 12 times each year, along with two additional issues of its Guide to Outsourcing supplement.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

Safe Harbor Statement

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
2. CardioGenics Featured on Canadas Business News Network
3. CardioGenics Holdings Inc. Receives New Ticker Symbol
4. CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer
5. New Corporate Profile Posted On CardioGenics Website
6. CardioGenics Announces Reverse Stock Split
7. CardioGenics Announces Update Regarding Status of Merck Agreement
8. CardioGenics to be Spotlighted in Three Publications During Month of April
9. CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
10. CardioGenics Announces Further Update Regarding Status of Merck Agreement
11. CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 CSSi, the ... for the clinical research industry, is proud to announce ... . The new website features both enriched content and ... experience and enhances the company,s already well-established position as ... "After many months of hard work, ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/9/2017)... PORTLAND, Ore. , May 9, 2017 /PRNewswire/ ... company that provides technology solutions to improve the ... reported financial results for the first quarter ended ... that our products enable our customers to identify ... them to intervene before events like heart attacks ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 26, 2017 , ... A May 8 article on CBCNews ... or respiratory issues that are not responsive to antibiotics nevertheless obtain prescriptions for them. ... largely responsible for the problem both in Canada and the United States. Dr. Michael ...
(Date:5/27/2017)... NY (PRWEB) , ... May 27, 2017 , ... From ... and Oticon. The three-day event was held at the Marriott Syracuse Downtown Hotel ... with the hearing brand and network of independent hearing healthcare providers to help them ...
(Date:5/26/2017)... NY (PRWEB) , ... May 26, 2017 , ... ... (SAB) met this week to review more than eighty-nine grant submissions all ... and emerging young scientists in the Parkinson’s field.     , The American Parkinson Disease ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the ... versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA ... to be the first in Arkansas to introduce the most powerful SCS system and ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, one ... for Memorial Day entertaining that are sure to satisfy your guests’ flavor cravings, ... meats and cheeses featured in these refreshingly balanced recipes are packed with flavor, ...
Breaking Medicine News(10 mins):